Related Experiment Video
Updated: Feb 18, 2026

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims
Jessica A Walsh1, Oluwakayode Adejoro2, Benjamin Chastek2
1University of Utah & Salt Lake City Veterans Affairs Medical Center, Division of Rheumatology, Salt Lake City, UT 84132, USA.
Aim:
Examine treatment patterns among patients with active ankylosing spondylitis (AS) treated with a TNF inhibitor (TNFi).
Patients & Methods:
Patients with AS who initiated a TNFi between 1 January 2013, and 31 January 2015, were identified in the Optum Research Database. Outcomes included adherence, persistence, discontinuation and therapy modifications of the index TNFi during 12-month follow-up.
Results:
Of the 426 patients included, 40.6% persisted on the index TNFi for ≥12 months, 31.0% discontinued, 21.4% switched to a different TNFi, and 7.0% discontinued and then restarted. Of the 333 patients who persisted on their TNFi for >90 days, 44.7% received ≥1 add-on medication.
Conclusion:
A high proportion of patients with AS switched, discontinued or modified their TNFi therapy.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD

